caplacizumab TTP
Selected indexed studies
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. (N Engl J Med, 2019) [PMID:30625070]
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. (N Engl J Med, 2016) [PMID:26863353]
- ADAMTS13 in the New Era of TTP. (Int J Mol Sci, 2024) [PMID:39125707]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. (2019) pubmed
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. (2016) pubmed
- ADAMTS13 in the New Era of TTP. (2024) pubmed
- ADAMTS13 recovery in caplacizumab-treated TTP. (2024) pubmed
- Thrombotic thrombocytopenic purpura. (2017) pubmed
- ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. (2020) pubmed
- Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. (2021) pubmed
- TTP and pregnancy. (2024) pubmed
- Immune Thrombotic Thrombocytopenic Purpura: A Review. (2025) pubmed
- Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project). (2025) pubmed